• Lead
• Features
• Development Stage
• Indications

5-HT_2C agonists for CNS disorders

• BMB-101
• • Highly selective 5-HT2C agonist
  • Biased agonism with minimal arrestin recruitment
  • Suitable for chronic dosing
  • Potential for pro-cognitive effects
• Clinical Studies - Phase 2
• Rare epilepsies

• BMB-xxx
• • Selective 5-HT_2Cagonist compound
  • Biased agonist
• Preclinical studies
• Obesity and feeding behaviour

Non-hallucinogenic Psychoplastogens

• BMB-201
• • Promotes neuroplasticity
  • Low or absent psychedelic activity
  • Devoid of 5-HT_2B activity
• Preclinical studies
• Treatment-resistant depression

5-HT_2A agonists for the treatment of depression

• BMB-202
• • Selective 5-HT_2a "Fast-On-Fast_Off" compound
  • High C_max and short plasma half life
  • 2-fold more potent than psilocin at 5-HT_2A
• Preclinical studies
• Depression

  (Fast-onset)

• BMB-xxx
• • Mixed 5-HT _2A/2C compound
  • 10-fold more potent than psilocin at 5-HT _2A
• Preclinical studies

• Neurology /
  Neuropsychiatric
  Indication